Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastrointestinal therapeutics

- PMLiVE

J&J fast-tracks Ebola vaccine

Human clinical trials set to begin in early 2015

- PMLiVE

AbbVie forges $1.5bn ageing disease alliance with Calico

Pharma company partners with Google’s health research business

- PMLiVE

Germany’s IQWiG denies Astellas’ incontinence drug

But Janssen receives recommendation for hepatitis C treatment Olysio

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

FDA approves J&J’s diabetes combo

Invokamet combines Invokana and metformin to help reduce blood sugar

- PMLiVE

Janssen looks to NASCAR for atrial fibrillation awareness

Company's MyAFibStory.com 400 kicks off the NASCAR Sprint Cup series

- PMLiVE

AbbVie begins ‘first-of-its-kind’ hep C charity pilot

Will work with Addaction Cornwall and The Hepatitis C Trust

- PMLiVE

Janssen launches online mental health video series

Healthy Minds will focus on brain disorder research and treatment

- PMLiVE

J&J’s Imbruvica wins new cancer indication

FDA backs drug’s use in chronic lymphocytic leukaemia patients with genetic mutation

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links